• Relative vs Fractional Viability in Cancer Drug Testing

  2026-09-10

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an in vitro cancer drug response. The framework supports better endpoint selection, time-course interpretation, and experimental designs that avoid labeling cytostatic effects as cytotoxicity.

• Pexidartinib: A Causal CSF1R Assay Framework

  2026-09-10

  Pexidartinib (PLX3397) enables a more precise test of how CSF1R-dependent myeloid cells shape tissue phenotypes. This article translates microglial seizure-susceptibility findings into a rigorous assay framework for cancer research and neuroimmune studies.

• Pazopanib (GW-786034) in ATRX Glioma Studies

  2026-09-09

  Build genotype-aware RTK experiments with Pazopanib (GW-786034), connecting ATRX status to viability, signaling, and angiogenesis readouts. This workflow combines concentration-controlled dosing, orthogonal validation, and TMZ combination testing for more interpretable cancer research.

• 7ACC2 and Lactate Flux: An Assay-First Guide

  2026-09-09

  7ACC2 is a monocarboxylate transporter 1 inhibitor that also perturbs mitochondrial pyruvate transport. This assay-first guide explains how to separate transport effects from broader immunometabolic hypotheses and design more interpretable cancer metabolism research.

• Clodronate Liposomes for Macrophage Studies

  2026-09-08

  Clodronate Liposomes provide a practical way to test whether macrophages causally shape tumor immunity, inflammation, or tissue repair in vivo. This guide connects macrophage depletion with orthogonal genetic and molecular assays, using colorectal cancer immunotherapy resistance as a model application.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-08

  The Annexin V-FITC/PI Apoptosis Assay Kit supports rapid separation of viable, early apoptotic, late apoptotic, and membrane-compromised cells using phosphatidylserine binding and PI uptake. It is suitable for research flow cytometry or fluorescence microscopy, but it should not be used alone to establish a specific death mechanism or for diagnostic or medical decisions.

• MLN8237 (Alisertib) Assay Workflows

  2026-09-07

  Build mechanism-focused Aurora A experiments with MLN8237 (Alisertib), from dose and timing pilots to mitotic, aneuploidy, and apoptosis readouts. The workflow combines cancer biology applications with a reference-informed strategy for separating kinase-driven chromosome missegregation from tubulin-mediated effects.

• In Vitro Drug Response: Beyond Viability Scores

  2026-09-07

  Hannah Schwartz’s dissertation shows that relative viability and fractional viability are related but non-equivalent measures of anticancer drug response. Its central contribution is a framework for separating proliferative arrest from cell killing and interpreting their different timing, improving the design and analysis of in vitro cancer research assays.

• Gastrin I (Human): CCK2 Receptor Research

  2026-09-05

  Gastrin I is a human Gastrin I peptide used to investigate CCK2 receptor signaling and gastric acid secretion. Its defined purity, solubility, and storage specifications make it a practical reagent for gastric acid secretion pathway research, while intestinal organoid applications require explicit model validation.

• miRNA–mRNA Control of Juvenile Hormone Biosynthesis

  2026-09-04

  This study identifies coordinated miRNA–mRNA modules that sustain juvenile hormone biosynthesis in the corpora allata of adult locusts during vitellogenesis. Its combination of transcriptomics, target validation, and agomiR perturbation connects post-transcriptional regulation with vitellogenin expression and ovarian development, providing a mechanistic framework for studying hormone-regulated development in insects.

• Npt1-Mediated Renal Secretion of Faropenem

  2026-09-04

  The 2000 reference study identified the renal inorganic phosphate transporter Npt1 as a luminal transport route for faropenem, clarifying how this penem antibiotic may undergo active tubular secretion. Using mouse Npt1 expressed in Xenopus oocytes, the authors connected chloride-sensitive uptake and enhanced efflux with a mechanistic model for renal elimination, while also defining important limits for translating the findings to human pharmacokinetics.

• (S)-(+)-Methoprene: Juvenile Hormone Analog

  2026-09-03

  (S)-(+)-Methoprene is a stereochemically defined juvenile hormone analog that activates the insect Met receptor pathway. It provides a downstream tool for separating juvenile hormone receptor signaling from endogenous hormone biosynthesis in developmental, reproductive, and arthropod endocrine studies.

• SHC-1 Inhibition and CFTR Membrane Trafficking

  2026-09-03

  A 2026 study shows that MAPK/SHC-1-dependent CFTR internalization extends beyond a single airway epithelial model, but pharmacological SHC-1 inhibition increases surface CFTR selectively in CFBE cells and also alters unrelated membrane proteins. The findings emphasize cell-context dependence and the need to distinguish CFTR trafficking rescue from nonspecific changes in plasma membrane composition.

• NMDA in Excitotoxicity and Glaucoma Models

  2026-09-02

  NMDA (N-Methyl-D-aspartic acid) provides a direct, controllable trigger for receptor-mediated excitotoxicity, calcium influx, and oxidative injury. This workflow translates the BMP4-GPX4 glaucoma study into practical assay design, from concentration scouting to ferroptosis-aware validation.

• Go 6983: Pan-PKC Inhibitor Research Guide

  2026-09-02

  Go 6983 is a pan-PKC inhibitor with strong reported activity against PKCα, PKCβ, PKCγ, and PKCδ. Its selectivity profile, DMSO solubility, and cell-based evidence support controlled PKC signaling pathway research, cancer progression studies, and epithelial-to-mesenchymal transition (EMT) assays.

7966 records 1/532 page Next 12345 下5页 Last page